Your browser doesn't support javascript.
loading
Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan.
Arashiro, Takeshi; Arima, Yuzo; Kuramochi, Jin; Muraoka, Hirokazu; Sato, Akihiro; Chubachi, Kumi; Yanai, Atsushi; Arioka, Hiroko; Uehara, Yuki; Ihara, Genei; Kato, Yasuyuki; Yanagisawa, Naoki; Ueda, Akihiro; Kato, Hideaki; Oka, Hideaki; Nishida, Yusuke; Nidaira, Yuki; Asami, Takahiro; Jinta, Torahiko; Nakamura, Akira; Oba, Kunihiro; Taniyama, Daisuke; Yamamoto, Kei; Tanaka, Katsushi; Ueshima, Kankuro; Fuwa, Tetsuji; Stucky, Ashley; Suzuki, Tadaki; Smith, Chris; Hibberd, Martin; Ariyoshi, Koya; Suzuki, Motoi.
Afiliação
  • Arashiro T; Center for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Tokyo, Japan.
  • Arima Y; Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.
  • Kuramochi J; Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Muraoka H; School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan.
  • Sato A; Center for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Tokyo, Japan.
  • Chubachi K; Kuramochi Clinic Interpark, Tochigi, Japan.
  • Yanai A; Department of Global Health Promotion, Tokyo Medical and Dental University, Tokyo, Japan.
  • Arioka H; CLINIC FOR TAMACHI, Tokyo, Japan.
  • Uehara Y; KARADA Internal Medicine Clinic, Tokyo, Japan.
  • Ihara G; Chubachi Internal Respiratory Medicine Clinic, Tokyo, Japan.
  • Kato Y; Department of General Internal Medicine, St. Luke's International Hospital, Tokyo, Japan.
  • Yanagisawa N; Department of General Internal Medicine, St. Luke's International Hospital, Tokyo, Japan.
  • Ueda A; Department of Clinical Laboratory, St. Luke's International Hospital, Tokyo, Japan.
  • Kato H; Department of Infectious Diseases, Fujita Health University School of Medicine, Aichi, Japan.
  • Oka H; Machida Ekimae Naika Clinic, Tokyo, Japan.
  • Nishida Y; Department of Infectious Diseases, International University of Health and Welfare Narita Hospital, Chiba, Japan.
  • Nidaira Y; Yanagisawa Clinic, Tokyo, Japan.
  • Asami T; Department of Infectious Diseases, Japanese Red Cross Medical Center, Tokyo, Japan.
  • Jinta T; Infection Prevention and Control Department, Yokohama City University Hospital, Yokohama, Japan.
  • Nakamura A; Department of General Internal Medicine and Infectious Diseases, Saitama Medical Center, Saitama, Japan.
  • Oba K; Department of General Internal Medicine and Infectious Diseases, Saitama Medical Center, Saitama, Japan.
  • Taniyama D; Kuramochi Clinic Interpark, Tochigi, Japan.
  • Yamamoto K; Department of Internal Medicine, Sano Kosei General Hospital, Tochigi, Japan.
  • Tanaka K; Department of Pulmonary Medicine, St. Luke's International Hospital, Tokyo, Japan.
  • Ueshima K; Department of Internal Medicine, Asahi General Hospital, Chiba, Japan.
  • Fuwa T; Department of Pediatrics, Showa General Hospital, Tokyo, Japan.
  • Stucky A; Department of Infectious Diseases, Showa General Hospital, Tokyo, Japan.
  • Suzuki T; Department of General Internal Medicine and Infectious Diseases, Saitama Medical Center, Saitama, Japan.
  • Smith C; Infection Prevention and Control Department, Yokohama City University Hospital, Yokohama, Japan.
  • Hibberd M; NATURALI Co., Ltd, Tokyo, Japan.
  • Ariyoshi K; NATURALI Co., Ltd, Tokyo, Japan.
  • Suzuki M; Center for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Tokyo, Japan.
Open Forum Infect Dis ; 10(6): ofad240, 2023 Jun.
Article em En | MEDLINE | ID: mdl-37351451
ABSTRACT
In this multicenter, prospective, test-negative, case-control study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent coronavirus disease 2019 mRNA vaccines against symptomatic infection during the BA.5-dominant period was high compared with no vaccination (65% and 76%) and moderate compared with monovalent vaccines administered over half a year earlier (46% combined).
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article